Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin After ESHAP in Relapsed Follicular Lymphoma
NCT00732498Phase 2Completed
- Sponsor
- University of Arizona
- Start
- May 2006
- Primary completion
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in follicular lymphoma (FL), sponsored by University of Arizona. Primary endpoints: Progression-free Survival at 1 Year and Median Time to Progression at 5 years. Started May 2006; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00732498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00732498.